Original Article

Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach

Correspondence to: Lars Berglund.

To differentiate effects of lovastatin on low density lipoprotein (LDL) receptor activity from effects on LDL metabolic properties, LDL apolipoprotein B (apoB) turnover was studied in eight hyperlipidemic subjects during baseline and lovastatin treatment, in the latter case with LDL tracers isolated during both baseline (C-LDL) and drug treatment (Rx-LDL) conditions. Lovastatin (40 mg/day) significantly lowered total plasma and LDL cholesterol levels (27% and 25%, respectively) as well as plasma triglyceride levels (30%). Using contemporaneous tracers (C-LDL before and Rx-LDL during treatment), lovastatin caused a modest increase in LDL fractional catabolic rate (FCR) (0.410 ± 0.113 vs. 0.339 ± 0.108 pools/day, P < 0.04 by paired t). The increase in LDL tracer FCR was higher when C-LDL tracer isolated during the untreated period was injected during lovastatin treatment (0.496 ± 0.177 vs. 0.339 ± 0.108 pools/day, P < 0.02). These in vivo studies in humans were confirmed by injecting LDL tracers from two patients into five guinea pigs. The C-LDL tracer was cleared consistently faster than the Rx-LDL tracer (0.082 ± 0.018 vs. 0.057 ± 0.015 pools/h, P < 0.001). The results demonstrate three important outcomes of lovastatin treatment in these subjects: LDL receptor activity increased by 49% (P < 0.02); LDL apoB production rate decreased by 17% (P < 0.03), and LDL particle in vivo affinity for the LDL receptor decreased by 15% (P < 0.01). The decrease in LDL particle affinity partially negated the expected effect of increased LDL receptors on LDL clearance.

The present study provides an explanation for earlier observations by several investigators using contemporaneous tracers that treatment with HMG-CoA reductase inhibitors resulted in only modest increases in low density lipoprotein functional catabolic rate.—Berglund, L., J. L. Witztum, N. F. Galeano, A. S. Khouw, H. N. Ginsberg, and R. Ramakrishnan. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. J. Lipid Res. 1998. 39: 913–924.

Supplementary key words: HMG-CoA reductase inhibitors, LDL receptor, apolipoprotein B, lipoprotein metabolism, tracer kinetics, lipid-lowering therapy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Berglund Lipoprotein Metabolism: A Well-Tried Tool to Characterize Dyslipidemic Mechanisms. Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1201 - 1203. [Full Text] [PDF]

				J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. Hugh, R. Barrett, F. K. Welty, A. Faruqi, M. L. Wolfe, C. Nartsupha, A. G. Digenio, et al. Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1350 - 1356. [Abstract] [Full Text] [PDF]

				M. Myerson, C. Ngai, J. Jones, S. Holleran, R. Ramakrishnan, L. Berglund, and H. N. Ginsberg Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia J. Lipid Res., December 1, 2005; 46(12): 2735 - 2744. [Abstract] [Full Text] [PDF]

				R. S Bruno, R. Ramakrishnan, T. J Montine, T. M Bray, and M. G Traber {alpha}-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status Am. J. Clinical Nutrition, January 1, 2005; 81(1): 95 - 103. [Abstract] [Full Text] [PDF]

				S. Lind, M. Rudling, S. Ericsson, H. Olivecrona, M. Eriksson, B. Borgstrom, G. Eggertsen, L. Berglund, and B. Angelin Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 349 - 356. [Abstract] [Full Text]

				P. R. W. de Sauvage Nolting, M. B. Twickler, G. M. Dallinga-Thie, R. J.A. Buirma, B. A. Hutten, J. J.P. Kastelein, and for the Examination of Probands and Relatives in S Elevated Remnant-Like Particles in Heterozygous Familial Hypercholesterolemia and Response to Statin Therapy Circulation, August 13, 2002; 106(7): 788 - 792. [Abstract] [Full Text] [PDF]

				C.J.M. Halkes, H. van Dijk, P.P.T. de Jaegere, H.W.M. Plokker, Y. van der Helm, D. W. Erkelens, and M. Castro Cabezas Postprandial Increase of Complement Component 3 in Normolipidemic Patients With Coronary Artery Disease: Effects of Expanded-Dose Simvastatin Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1526 - 1530. [Abstract] [Full Text] [PDF]

				M. L. Fernandez Guinea Pigs as Models for Cholesterol and Lipoprotein Metabolism J. Nutr., January 1, 2001; 131(1): 10 - 20. [Abstract] [Full Text]

				M. A. Latour, B. W. Patterson, R. T. Kitchens, R. E. Ostlund Jr, D. Hopkins, and G. Schonfeld Effects of Alcohol and Cholesterol Feeding on Lipoprotein Metabolism and Cholesterol Absorption in Rabbits Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 598 - 604. [Abstract] [Full Text] [PDF]